Page 11234..»

Archive for the ‘Hypogonadism’ Category

Emerging Clinical Tool Predicts Risk of Persistent Use of Opioids After Treatment in Patients With Cancer – Cancer Therapy Advisor

The opioidepidemic imposes scrutiny on clinicians and patients alike; with particularemphasis on cancer survivors who require the drugs to manage their pain. Howdoes the clinician determine who is at risk for persistent opioid use andabuse? A group of radiation oncologists and pain specialists from theUniversity of California San Diego (UCSD) conducted a study to answer thisvital question, and presented their findings at the 2019 American Society forRadiation Oncology (ASTRO) Annual Meeting, held in Chicago.1

More than 50% of oncology patients who receive curative treatmentsuffer from moderate to severe pain that can be relieved by opioids, according toWHO pain guidelines.2 Although these medications are accepted forrelief of such acute pain, their use in situations where patients have chronicpain (lasting for more than 3 to 6 months) is not so well defined. There arerisks of such long-term administration, such as medication tolerance and lossof efficacy over time. The potential of toxicity can lead to conditions such asdepression, difficulty concentrating, and sedation, and the patient may alsodevelop hyperalgesia or hypogonadism. There are also the well-known risks ofdependence, misuse and abuse, and accidental overdose. The authors of thisstudy support adopting the clinical practice guideline of the American Societyof Clinical Oncology (ASCO) when using opioids to achieve optimal pain management,using risk mitigation strategies such as judicious opioid use, drug screening,adherence monitoring, and strategies for alternative pain management.1,3

Creating a Risk Score

The radiation oncologists sought to identify clinical risk factors and create a risk score, utilizing an evidence-based risk stratification approach to identify patients who might benefit from a proactive approach by the oncology nurse or other clinician. Their efforts resulted in the Cancer Opioid Risk Tool, a validated prediction tool for assessing the risk of persistent opioid use 1 to 2 years after treatment, estimating risk aslow (less than 5%), intermediate (5% to 25%) and high (greater than 25%).

The researchers usedthe Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI)database, which contains detailed electronic health record information on allveterans within the VA health care system. This database provided data on106,732 veteran cancer survivors whose cancer had been diagnosed between 2000and 2015.1

Common diagnosesamong the VA patients were 1 of 12 noncutaneous, nonhematologic malignancies,including cancer of the bladder, breast, colon, esophagus, head and neck,kidney, liver, lung, pancreas, prostate, rectum, or stomach. The study groupincluded patients who were treated with surgery, radiation therapy (RT), orboth and who were alive without disease recurrence 2 years after treatment hadbegun.1

Two models of the Cancer Opioid Risk Tool are available on the website: Full and Lite. Using an automated algorithm, the risk for persistent opioid use is calculated based on data entered by the clinician. The lite model uses 5 variables: age, presence of depression, alcohol abuse, prior opioid use, and whether treatment included chemotherapy. The more complex, full, model uses these 5 variables plus employment status, psychiatric diagnoses, race, tobacco use, body mass index (BMI) category, type of cancer, disease stage, and local treatment. (Note, although improvements to the tool are ongoing, it is totally functional.) The full version is recommended if providers have time and access to all of the relevant information.

This article originally appeared on Oncology Nurse Advisor

The rest is here:
Emerging Clinical Tool Predicts Risk of Persistent Use of Opioids After Treatment in Patients With Cancer - Cancer Therapy Advisor

Jayson Tatum, Celtics really bringing in the green at merchandise stand – The Boston Globe

The Celtics were No. 2 in team merchandise sold from October through December at NBA-Store.com, with Jayson Tatum fourth in jersey sales. The Los Angeles Lakers and LeBron James topped their respective lists, according to the latest numbers put out by the league. The top-10 jerseys belonged to James, reigning MVP Giannis Antetokounmpo, Golden States Stephen Curry, Tatum, Houstons James Harden, Luka Doncic of Dallas, new Los Angeles Clipper Kawhi Leonard, LeBrons new Lakers teammate Anthony Davis, Philadelphias Joel Embiid, and Brooklyns Kyrie Irving was 10th. Kemba Walker ranked 14th, just ahead of No. 1 overall pick Zion Williamson ... Changes to the NBA schedule in time for the 75th anniversary season in 2021-22 remain a real possibility, but the leagues board of governors likely wont vote on them in April, according to an Associated Press source. Suggestions include a 78-game regular season, an in-season tournament in November and December, and a reseeding of the playoffs prior to the final four ... Two-time All-Star Karl-Anthony Towns was in the starting lineup for Minnesota at Indiana after missing 15 games with a sprained left knee.

Major League Baseball has never issued a therapeutic use exemption for human growth hormone, the league and Major League Baseball Players Association announced in response to an allegation that four-time AL MVP Mike Trout has been secretly using HGH as treatment for a fabricated thyroid condition. An Instagram account purportedly run by David Brosius, son of 11-year major leaguer Scott Brosius, posted the claim, citing information gleaned while his father was Seattles third-base coach in 2017. (The elder Brosius was an assistant coach with the Mariners in 2017, and their third-base coach in 2018.) The account was deleted after social media site Reddit found the post, but then reactivated so David Brosius could apologize, claiming the story was a hypothetical with no evidence behind it. MLB issued 91 therapeutic use exemptions for ADHD drugs last season, according to the MLB/MLBPA annual report, plus one each for hypersomnia, hypogonadism, and kidney disease ... Houston Astros owner Jim Crane said he has interviewed a number of candidates, and expects to hire a replacement for fired manager A.J. Hinch by Feb. 3. He added that he expects most of Hinchs staff to stay in place ... Former Walmart Inc. chief executive David Glass, 84, who owned the Kansas City Royals for nearly two decades before selling the franchise for $1 billion last fall, died on Jan. 9 of complications from pneumonia. Glasss Royals reached the World Series twice and won it in 2015, but had just four winning seasons in his 20 years as owner ... The Colorado Rockies will retire the No. 33 of outfielder Larry Walker, a Hall of Fame contender in his final year on the writers ballot, on April 19 ... Reliever Craig Stammen finalized a $9 million, two-year contract to remain with the San Diego Padres.

The No. 5 Boston College mens hockey team weathered two UMass Lowell goals in the first 71 seconds at Tsongas Center, coming back to beat the No. 13 River Hawks, 3-2. Marc McLaughlin, Alex Newhook, and Logan Hutsko had the answer for the Eagles (14-5-0, 8-3-0 Hockey East), whove won 12 of 13 ... Mitchell Chaffee made it a hat trick with an empty-netter in the final seconds for No. 7 UMass (15-7-1, 8-4-1), which dominated host Vermont, 4-0 ... Third-period goals from sophomores Jake Wise and Jack DeBoer gave BU (8-7-5, 5-3-4) a 3-2, come-from-behind win at Merrimack ... No. 16 Harvard (9-5-2, 7-3-1 ECAC) scored three times on the power play, Jack Drury adding an assist in a 3-1 home win over St. Lawrence ... Sophomore Alexis Hills double-double, with 17 points and 16 rebounds, helped lead Northeastern (7-8, 3-1 Colonial Athletic) womens basketball to a 68-65, overtime victory over Elon at Cabot Center.

Two-time Atlantic Coast Conference player of the year Travis Etienne is returning to Clemson for his senior season, the junior running back announced on social media. Etienne was projected as a second-round selection after he gained 1,614 yards and 19 touchdowns this season ... Declaring of quarterback Joe Burrow, we call him young Tom Brady, president Donald Trump feted national champion LSU at the White House, saying the undefeated Tigers would long be remembered as one of the greatest in college football history ... Boston College announced Matt Thurin, an Ohio State defensive quality control coach the last five seasons, as its special teams coordinator under new coach Jeff Hafley. Hafley worked with Thurin on the OSU staff for one year.

Carolina Hurricanes defenseman Dougie Hamilton, a first-time All-Star, had surgery and is out indefinitely after he broke his left leg Thursday, getting tangled with Columbus Kevin Stenlund during a chase for the puck. The 26-year-old has 14 goals and 40 points in 47 games, second and fourth respectively among NHL defensemen ... Former Whitman-Hanson star midfielder Sam Mewis was named among the 20 players that will compete from the United States in the upcoming CONCACAF Olympic qualifying womens soccer tournament. Five of her teammates from the Womens World Cup champions last summer were not, including Alex Morgan, whos expecting her first child, and promising young forward Mallory Pugh. Eighteen of the 20 spots went to players from the World Cup squad, including one to Carli Lloyd, who will turn 38 before the Tokyo Games and was largely a reserve in France. The charges of Vlatko Andonovski, who took over last October after Jill Ellis stepped down, open qualifying on Jan. 28 in Houston against Haiti. The United States has made the field for every Olympic tournament since womens soccer was added to the Games in 1996, and has won four gold medals ... American star Christian Pulisics adductor injury appears likely to keep him out of Chelseas lineup until mid-February. The 21-year-old attacker has not played since New Years Day, and has six goals and six assists in all competitions this season.

Go here to see the original:
Jayson Tatum, Celtics really bringing in the green at merchandise stand - The Boston Globe

North America Hormone Replacement Therapy Market Expected to Generate a Value of US $4.7 Billion by 2024 – ResearchAndMarkets.com – Yahoo Finance

The "North America Hormone Replacement Therapy Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

The publisher expects the market to reach a value of US$ 4.7 Billion by 2024, registering a CAGR of 5.35% during 2019-2024.

The North America hormone replacement therapy market reached a value of US$ 3.5 Billion in 2018. Hormone replacement therapy (HRT) is used for replenishing hormones that are present in low levels in the human body. This treatment is particularly favorable for patients who are experiencing growth hormone deficiency, women nearing menopause and older people suffering from hypogonadism. HRT is available in several forms such as gels, injections, implants, and skin and mouth patches (transdermal). However, it may not be suitable for patients that have a record of blood clots, liver disease and untreated high blood pressure.

North America hormone replacement therapy market is currently being driven by several factors. A surge in the incidences of hormone imbalance disorders, especially in the geriatric and neonatal populations, is spurring the demand for HRT in North America. In line with this, the rising need for new treatment options with better safety results is further catalyzing the market growth in the region. Apart from this, increasing R&D activities for hormone replacement products is enhancing their quality and efficiency. Additionally, the increasing consumer awareness, coupled with the rising technological innovations, such as new gel-based formulations, have also spurred the demand for hormone replacement products in the region.

Key Questions Answered in This Report:

Report Coverage:

Key Topics Covered:

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Hormone Replacement Therapy Market

5.1 Market Performance

5.2 Market Breakup by Product

5.3 Market Breakup by Route of Administration

5.4 Market Breakup by Type of Disease

5.5 Market Breakup by Region

5.6 Market Forecast

6 North America Hormone Replacement Therapy Market

6.1 Market Performance

6.2 Market Forecast

7 North America Hormone Replacement Therapy Market: Breakup by Product

7.1 Estrogen Replacement Therapy

7.2 Human Growth Hormone Replacement Therapy

7.3 Thyroid Replacement Therapy

7.4 Testosterone Replacement Therapy

7.5 Others

8 North America Hormone Replacement Therapy Market: Breakup by Route of Administration

8.1 Oral

8.2 Parenteral

8.3 Transdermal

9 North America Hormone Replacement Therapy Market: Breakup by Type of Disease

9.1 Menopause

9.2 Hypothyroidism

9.3 Male Hypogonadism

9.4 Growth Hormone Deficiency

9.5 Others

10 North America Hormone Replacement Therapy Market: Breakup by Country

10.1 United States

10.1.1 Historical market Trends

10.1.2 Market Breakup by Product

10.1.3 Market Breakup by Route of Administration

10.1.4 Market Breakup by Type of Disease

10.1.5 Market Forecast

10.2 Canada

10.3 Mexico

11 SWOT Analysis

11.1 Overview

11.2 Strengths

11.3 Weaknesses

11.4 Opportunities

11.5 Threats

12 Value Chain Analysis

12.1 Overview

12.2 Research and Development

12.3 Raw Material Procurement

12.4 Manufacturing

12.5 Marketing

12.6 Distribution

12.7 End-Use

13 Porter's Five Forces Analysis

13.1 Overview

13.2 Bargaining Power of Buyers

13.3 Bargaining Power of Suppliers

13.4 Degree of Rivalry

13.5 Threat of New Entrants

13.6 Threat of Substitutes

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/xr45u2

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005380/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the article here:
North America Hormone Replacement Therapy Market Expected to Generate a Value of US $4.7 Billion by 2024 - ResearchAndMarkets.com - Yahoo Finance

Reproductive health: What is hypogonadism? Know the symptoms, causes, and prevention of the condition – Times Now

Reproductive health: What is Hypogonadism? Know the symptoms, causes, and prevention of the condition  |  Photo Credit: Getty Images

New Delhi: Reproductive and sexual health may not be topics of drawing-room conversations, but that does not deem them unimportant. Reproductive health and sexual health are closely knit and need more attention than people give the concerns, since people suffering from problems may find it difficult to speak up, visit a doctor, and talk about their symptoms.

When it comes to sexual health, there is no 'one size fits all' solution, which makes it even more important to raise awareness. Various factors that include personal, gynaecological, and physical factors can affect sexual health and cause different types of disorders or problems. One such sexual health issue is that of hypogonadism, that many men and women may experience, but few are aware of.

Hypogonadism is a condition defined as the diminished functional activity of the gonads the testes in men, and the ovaries in women. This may result in diminished production of sex or reproductive hormones, and may adversely affect sexual and reproductive health. It is a pretty common condition, and sees about more than a million cases every year, in India alone.

The symptoms of the condition vary for both the genders, while some may be common for both. Fatigue, hot flashes, difficulty in concentrating, infertility, loss of body hair are some of the common symptoms. Other symptoms include -

For women

For men

The causes behind the condition can be various. Ranging from genetic disorder to autoimmune disorders, infections, diseases, radiation exposure, etc. can also cause the condition. Since the causes are difficult to identify, it is always advisable to visit the doctor if you see any symptoms of the condition.

Lifestyle factors that can cause the condition include obesity, rapid weight loss, nutritional deficiencies, and the use of steroids or opioids.

There are no specific ways to prevent the condition. However, a recent study has shown that losing weight can help in treating testosterone levels in men. A healthy lifestyle and diet, regular physical activity or exercise, and a healthy diet play an important role in keeping the risk of diseases at bay and preventing conditions like hypogonadism. For better sexual health, refraining from smoking, binge drinking, and use of drugs is also recommended.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read the rest here:
Reproductive health: What is hypogonadism? Know the symptoms, causes, and prevention of the condition - Times Now

Short Interest in Aytu Bioscience Inc (NASDAQ:AYTU) Increases By 75.1% – Riverton Roll

Aytu Bioscience Inc (NASDAQ:AYTU) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 735,800 shares, an increase of 75.1% from the December 15th total of 420,100 shares. Approximately 4.5% of the companys stock are short sold. Based on an average trading volume of 125,500 shares, the short-interest ratio is currently 5.9 days.

AYTU stock opened at $0.80 on Friday. Aytu Bioscience has a twelve month low of $0.65 and a twelve month high of $2.61. The stocks 50 day moving average is $0.86 and its 200-day moving average is $1.24. The firm has a market capitalization of $16.48 million, a PE ratio of -0.23 and a beta of 4.61.

Aytu Bioscience (NASDAQ:AYTU) last posted its earnings results on Thursday, November 14th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.30) by ($0.02). Aytu Bioscience had a negative net margin of 390.43% and a negative return on equity of 252.42%. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $1.45 million. On average, research analysts expect that Aytu Bioscience will post -1.3 EPS for the current year.

In other news, CEO Joshua R. Disbrow purchased 55,000 shares of the businesss stock in a transaction on Thursday, December 19th. The shares were acquired at an average price of $0.83 per share, for a total transaction of $45,650.00. Also, major shareholder Armistice Capital Master Fund purchased 78,788 shares of the businesss stock in a transaction on Friday, December 20th. The stock was purchased at an average price of $0.90 per share, for a total transaction of $70,909.20. 5.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Aytu Bioscience in the second quarter valued at approximately $36,000. Virtu Financial LLC purchased a new stake in shares of Aytu Bioscience during the third quarter valued at approximately $36,000. Bank of New York Mellon Corp purchased a new stake in shares of Aytu Bioscience during the second quarter valued at approximately $75,000. Finally, Searle & CO. increased its position in shares of Aytu Bioscience by 24.1% during the third quarter. Searle & CO. now owns 249,848 shares of the companys stock valued at $302,000 after acquiring an additional 48,601 shares during the last quarter. Institutional investors own 27.76% of the companys stock.

A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered Aytu Bioscience from a hold rating to a sell rating in a report on Tuesday, December 17th. LADENBURG THALM/SH SH raised their target price on Aytu Bioscience from $4.00 to $4.75 in a report on Wednesday, September 18th. Northland Securities assumed coverage on Aytu Bioscience in a report on Friday, November 15th. They issued a buy rating and a $5.00 target price on the stock. Finally, ValuEngine lowered Aytu Bioscience from a buy rating to a hold rating in a report on Tuesday, December 24th.

About Aytu Bioscience

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Featured Article: What does the Dogs of the Dow mean?

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Short Interest in Aytu Bioscience Inc (NASDAQ:AYTU) Increases By 75.1% - Riverton Roll

Massive Growth of Testosterone Therapy Market by 2025 with Top Key Players like AbbVie Inc, Actavis Inc, Eli Lilly & Co, Auxilium Pharmaceuticals…

Testosterone Therapy Market research report comprises innovative tool in order to evaluate overall scenario of Industry along with its opportunities, and supporting strategic and tactical decision-making. Report analyzes changing trends and competitive analysis which becomes essential to monitor performance and make critical decisions for growth and development. It also provides market information in terms of development and its capacities.

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.

Get Sample copy of this Report @:

http://www.a2zmarketresearch.com/sample?reportId=115440

Top Vendors covered in this Report includes: AbbVie Inc, Actavis Inc, Eli Lilly & Co, Auxilium Pharmaceuticals.

The major strategies adopted by the established players for a better penetration in the global Testosterone Therapy market also form a key section of this study. These strategies can be employed by the upcoming vendors for a better penetration in the market. The global market on Incinerator has also been analyzed in terms of revenue. The market dynamics such as market drivers, challenges, opportunities, and trends have been presented coupled with their respective impact analysis. The impact analysis helps in gathering information on the future development of the market.

In this Testosterone Therapy Market research report, the prominent factors driving the advancement of this market were recorded and the business accomplices and end administrators were indulgent. The setup of the business division, examples, and challenges monitoring the market comprehensively are in like manner a bit of this wide examination. Different meetings and social events were driven by the distinguishable pioneers of this industry to get persisting and revived encounters concerned to the market.

What Makes Our Report Unique?

1) An extensive research study on the Global Testosterone Therapy Market, and its entire ecosystem, describes the market trends, drivers, restraints and opportunities of the Testosterone Therapy Market.

2) We provide you the longest possible market segmentation based on type of products, procedures and geography and describe the market share region wise.

3) The report gives a bird eyes view on the competitive landscape which includes mergers and acquisitions, collaborations, market strategies, and new product launches.

Get Upto 30% Discount on first Purchase of this report @:

http://www.a2zmarketresearch.com/discount?reportId=115440

Key questions answered in the report include:

If You Have Any Query, Ask Our Experts:

http://www.a2zmarketresearch.com/enquiry?reportId=115440

Table of Contents

Global Testosterone Therapy Market Research Report 2020-2025

Chapter 1 Testosterone Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Testosterone Therapy Market Forecast

If you have any special requirements, please let us know and we will offer you the report as you want.

Original post:
Massive Growth of Testosterone Therapy Market by 2025 with Top Key Players like AbbVie Inc, Actavis Inc, Eli Lilly & Co, Auxilium Pharmaceuticals...

Aytu Bioscience (NASDAQ:AYTU) Stock Rating Lowered by ValuEngine – Riverton Roll

ValuEngine cut shares of Aytu Bioscience (NASDAQ:AYTU) from a buy rating to a hold rating in a report published on Tuesday, December 24th, ValuEngine reports.

Several other research firms have also recently commented on AYTU. Northland Securities started coverage on shares of Aytu Bioscience in a report on Friday, November 15th. They set a buy rating and a $5.00 price target on the stock. Zacks Investment Research lowered Aytu Bioscience from a hold rating to a sell rating in a report on Tuesday, December 17th. Finally, LADENBURG THALM/SH SH boosted their target price on Aytu Bioscience from $4.00 to $4.75 in a research note on Wednesday, September 18th.

NASDAQ AYTU traded down $0.05 during trading on Tuesday, reaching $0.85. 69,438 shares of the companys stock were exchanged, compared to its average volume of 99,631. The firm has a market capitalization of $18.59 million, a PE ratio of -0.24 and a beta of 4.61. Aytu Bioscience has a fifty-two week low of $0.65 and a fifty-two week high of $2.61. The companys fifty day simple moving average is $0.86 and its 200-day simple moving average is $1.25.

Aytu Bioscience (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Aytu Bioscience had a negative return on equity of 252.42% and a negative net margin of 390.43%. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.45 million. As a group, sell-side analysts expect that Aytu Bioscience will post -1.3 earnings per share for the current fiscal year.

In other Aytu Bioscience news, CEO Joshua R. Disbrow bought 55,000 shares of the stock in a transaction on Thursday, December 19th. The shares were purchased at an average cost of $0.83 per share, with a total value of $45,650.00. Also, major shareholder Armistice Capital Master Fund bought 78,788 shares of the businesss stock in a transaction on Friday, December 20th. The shares were bought at an average price of $0.90 per share, for a total transaction of $70,909.20. Insiders own 5.80% of the companys stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Aytu Bioscience during the 2nd quarter valued at about $36,000. Virtu Financial LLC acquired a new stake in Aytu Bioscience in the 3rd quarter worth approximately $36,000. Bank of New York Mellon Corp acquired a new stake in Aytu Bioscience in the 2nd quarter worth approximately $75,000. Finally, Searle & CO. boosted its position in Aytu Bioscience by 24.1% during the third quarter. Searle & CO. now owns 249,848 shares of the companys stock worth $302,000 after purchasing an additional 48,601 shares during the period. Institutional investors own 27.76% of the companys stock.

Aytu Bioscience Company Profile

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

See Also: How is the LIBOR rate calculated?

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

The rest is here:
Aytu Bioscience (NASDAQ:AYTU) Stock Rating Lowered by ValuEngine - Riverton Roll

BLS Pharma Alleges Inovio’s Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender…

SANTA ANA, Calif.--(BUSINESS WIRE)-- BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system that BLS Pharma was using to develop a drug-device combination (DDC) for testosterone replacement therapy.

Testosterone replacement therapy is a multi-billion-dollar market primarily used to treat male hypogonadism, a condition in which the body fails to produce enough testosterone. It is also a necessary treatment for transgender individuals transitioning and on lifetime hormone therapy from female to male.

Testosterone replacement therapy can make a significant difference for those in need of treatment. Our product would have allowed users to administer their treatments from the comfort of their own homes using a virtually painless needle-free system, said Mark Logomasini, President & CEO of BLS Pharma.

The shareholders of BLS Pharma previously developed the needleless injector technology, called Zetajet, and sold the intellectual property rights for it to Inovio and Genetronics, with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request. Under the agreement, BLS Pharma ordered 25,000 Zetajet units to prepare for its clinical trials on the DDC and was assured that the order was in process.

In September, BLS Pharma and Genetronics discussed the logistics of the syringe supply, and BLS Pharmas plan to offer the product for patients with hypogonadism and as a treatment for transgender males. The next business day, Inovio and Genetronics informed BLS Pharma they would not be supplying the syringes. This breach of contract eliminated BLS Pharmas ability to bring the DDC to market.

We are disappointed that we cannot offer this solution for male hypogonadism and to the transgender community, who have historically been marginalized by the medical and pharmaceutical community, stated Logomasini.

The testosterone treatment market is valued at 1.3 to 1.8 billion dollars annually. BLS Pharmas lost profits due to the breach of contract are estimated to be at least $72,900,000. All media inquiries should be directed to Jason Hartley of the Hartley LLP law firm at (619) 400-5822. For a copy of the complaint, email karen@fullkorrpress.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005928/en/

Excerpt from:
BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender...

Massive Growth of Testosterone Replacement Therapy Market by 2025 with Top Key Players like AbbVie, Endo International, Eli lilly, Pfizer, Actavis…

Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development. Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.

Get Sample copy of this Report @:

http://www.a2zmarketresearch.com/sample?reportId=56158

Top Key Players covered in this Report includes: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals.

The report evaluates the figures of the global Testosterone Replacement Therapy market and presents reliable forecasts as to the markets growth prospects over the coming years. The historical development trajectory of this market is examined in the report, offering solid factual support to the analysis and estimations presented in the report. The geographical and competitive dynamics of this global market are also presented in the report, helping deliver a comprehensive picture of the market.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Testosterone Replacement Therapy market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Testosterone Replacement Therapy market

Get Upto 30% Discount on first Purchase of this report @:

http://www.a2zmarketresearch.com/discount?reportId=56158

As the global Testosterone Replacement Therapy market is segmented based on various parameters, an in-depth classification of the market is also mentioned; elements impacting the markets growth are studied in detail to understand the report precisely. Moreover this, profiles of some of the leading players operating in the global Testosterone Replacement Therapy market are included in the report. Using SWOT analysis, their weaknesses and strengths are analyzed. It helps the study deliver visions into the opportunities and threats that companies may face during the forecast period.

Reason for buy this market report?

For More Information, Visit @:

http://www.a2zmarketresearch.com/enquiry?reportId=56158

Table of Contents

Global Testosterone Replacement Therapy Market Research Report 2020-2025

Chapter 1 Testosterone Replacement Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Testosterone Replacement Therapy Market Forecast

Conclusion: This exclusive report will provide you a clear view of each and every fact of the Testosterone Replacement Therapy market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read more from the original source:
Massive Growth of Testosterone Replacement Therapy Market by 2025 with Top Key Players like AbbVie, Endo International, Eli lilly, Pfizer, Actavis...

Male Hypogonadism Guidelines: Opt for IM Testosterone – MedPage Today

Men with low testosterone should go for intramuscular rather than transdermal replacement formulations, according to a new clinical practice guideline from the American College of Physicians (ACP).

In the guideline, which was also endorsed by the American Academy of Family Physicians, the ACP recommends providers prescribe intramuscular testosterone when initiating treatment for men with age-related low testosterone or male hypogonadism -- defined as a testosterone threshold of 300 ng/dL or less.

Although both types of testosterone proved effective with similar risk profiles for improving sexual functioning in men with low testosterone, cost was the major differentiating factor.

On average, using an intramuscular formulation of testosterone would cost approximately $156.32 per patient per year versus $2,135.32 for a transdermal formation, explained Amir Qaseem, MD, PhD, of the American College of Physicians in Philadelphia, and colleagues.

The guideline, appearing in Annals of Internal Medicine, also recommended that testosterone should only be prescribed to men with age-related low testosterone with sexual dysfunction. Based on low-certainty evidence, the guideline suggested providers introduce this conversation to patients to individually weigh the benefits and risks of initiating testosterone replacement specifically for improving sexual dysfunction.

In an accompanying editorial, E. Victor Adlin, MD, of the Lewis Katz School of Medicine at Temple University in Philadelphia, noted that these recommendations are largely in line with what the rest of the medical community recommends, including recent guidelines from the Endocrine Society and the American Urological Association.

However, Adlin wasn't quite sold on the ACP's recommendation for intramuscular over transdermal formulation solely based on cost, saying that this recommendation "will be questioned by many clinicians."

"[T]he need for an intramuscular injection every 1 to 4 weeks is a potential barrier to adherence, and some patients require visits to a health care facility for the injections, which may add to the expense," he explained, adding that "peak-and-valley blood levels after each injection may cause irregularity of symptom relief and difficulty achieving the desired blood level. Individual preference may vary widely in the choice of testosterone therapy."

But ACP President Robert McLean, MD, pointed out in a statement that "[m]ost men are able to inject the intramuscular formulation at home and do not require a separate clinic or office visit for administration."

In an accompanying systematic review, Susan Diem, MD, MPH, of the Minneapolis VA Health Care System in Minnesota, and colleagues, found little to no benefit of testosterone therapy for symptoms other than sexual dysfunction in this patient population.

Looking at 38 randomized controlled trials of either transdermal or intramuscular testosterone-replacement therapy versus no therapy, the researchers found that testosterone had a small improvement in global sexual function score based on moderate-certainty evidence (standardized mean differences 0.35, 95% CI 0.23-0.46, I2=0%). There was also a small improvement shown in erectile function with testosterone therapy (SMD 0.27, 95% CI 0.09-0.44).

However, testosterone therapy -- regardless of formulation -- did not improve other symptoms of age-related male hypogonadism including lack of energy or vitality, physical functioning, and cognition. The analysis was underpowered to draw conclusions regarding testosterone's effect on mortality, the guideline authors pointed out.

Based on this evidence report data, the guideline recommends against initiating testosterone treatment for these particular symptoms.

Low certainty evidence also found little or no difference in adverse cardiovascular events with testosterone therapy, while moderate evidence found no evidence of any increased risk for serious adverse events.

"[M]en with age related low testosterone should not be prescribed testosterone treatment unless its purpose is to treat sexual function issues," the guideline concluded.

"Given that testosterone's effects were limited to small improvements in sexual and erectile function in men with low testosterone levels, it is unlikely that screening men for low testosterone levels or treating men without sexual or erectile dysfunction and low testosterone levels would be effective," McLean added in his statement.

As for the length of treatment, the guideline suggests that healthcare providers reevaluate the patient's symptoms of sexual dysfunction within 12 months of testosterone therapy, based on low-certainty evidence. For those patients who show no improvement in sexual dysfunction, therapy should be discontinued.

Ultimately, the guideline underscores that providers should give "full consideration of the patient's values and wishes" when initiating testosterone therapy.

Last Updated January 06, 2020

Disclaimer

The guideline and review were funded by the American College of Physicians.

Qaseem reported no conflicts of interest; one guideline co-author reported being a fiduciary officer for the Washington State Medical Association, and another being an employee of Kaiser Permanente.

McLean is an employee of Northeast Medical Group of Yale New Haven Health in Connecticut.

Review author Diem reported grants from the National Institute on Aging.

Read the original post:
Male Hypogonadism Guidelines: Opt for IM Testosterone - MedPage Today

Short Interest in Aytu Bioscience Inc (NASDAQ:AYTU) Expands By 13.2% – Riverton Roll

Aytu Bioscience Inc (NASDAQ:AYTU) was the recipient of a large increase in short interest during the month of December. As of December 13th, there was short interest totalling 420,100 shares, an increase of 13.2% from the November 28th total of 371,000 shares. Based on an average daily trading volume, of 132,400 shares, the short-interest ratio is currently 3.2 days. Currently, 2.6% of the shares of the company are short sold.

NASDAQ AYTU traded down $0.03 on Friday, hitting $0.98. 112,225 shares of the company traded hands, compared to its average volume of 149,923. The businesss 50 day moving average price is $0.85 and its 200-day moving average price is $1.30. Aytu Bioscience has a 52-week low of $0.65 and a 52-week high of $2.61. The company has a market capitalization of $21.09 million, a price-to-earnings ratio of -0.28 and a beta of 4.53.

Aytu Bioscience (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, November 14th. The company reported ($0.32) EPS for the quarter, missing analysts consensus estimates of ($0.30) by ($0.02). Aytu Bioscience had a negative return on equity of 252.42% and a negative net margin of 390.43%. The company had revenue of $1.44 million during the quarter, compared to analysts expectations of $1.45 million. As a group, analysts anticipate that Aytu Bioscience will post -1.3 EPS for the current year.

Several analysts recently issued reports on AYTU shares. LADENBURG THALM/SH SH boosted their target price on shares of Aytu Bioscience from $4.00 to $4.75 in a research report on Wednesday, September 18th. Zacks Investment Research downgraded shares of Aytu Bioscience from a hold rating to a sell rating in a research report on Tuesday, December 17th. ValuEngine cut shares of Aytu Bioscience from a buy rating to a hold rating in a research note on Tuesday. Finally, Northland Securities assumed coverage on shares of Aytu Bioscience in a research report on Friday, November 15th. They set a buy rating and a $5.00 price objective for the company.

In other Aytu Bioscience news, CEO Joshua R. Disbrow acquired 55,000 shares of the stock in a transaction dated Thursday, December 19th. The shares were purchased at an average price of $0.83 per share, for a total transaction of $45,650.00. Also, major shareholder Armistice Capital Master Fund acquired 78,788 shares of the stock in a transaction dated Friday, December 20th. The stock was acquired at an average price of $0.90 per share, for a total transaction of $70,909.20. Company insiders own 5.80% of the companys stock.

Several hedge funds have recently bought and sold shares of AYTU. BlackRock Inc. bought a new position in shares of Aytu Bioscience during the 2nd quarter valued at approximately $36,000. Virtu Financial LLC purchased a new stake in Aytu Bioscience in the 3rd quarter worth approximately $36,000. Bank of New York Mellon Corp bought a new stake in Aytu Bioscience during the 2nd quarter worth approximately $75,000. Finally, Searle & CO. raised its stake in Aytu Bioscience by 24.1% during the 3rd quarter. Searle & CO. now owns 249,848 shares of the companys stock worth $302,000 after acquiring an additional 48,601 shares during the period. 27.76% of the stock is currently owned by hedge funds and other institutional investors.

About Aytu Bioscience

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Recommended Story: How to interpret the current ratio

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original post:
Short Interest in Aytu Bioscience Inc (NASDAQ:AYTU) Expands By 13.2% - Riverton Roll

Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu…

ENGLEWOOD, CO and SAN DIEGO, CA / ACCESSWIRE / December 24, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 containing a joint preliminary proxy statement/prospectus in connection with Aytu BioScience's proposed acquisition of Innovus Pharmaceuticals on December 23, 2019 after markets closed.

The registration statement containing the joint preliminary proxy statement/prospectus is available through the SEC's website at http://www.sec.gov and on each company's website on the respective company's Investor section.

As previously announced the companies signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing, including amounts owed from Innovus to Aytu under a promissory note (currently $1.35 million principal amount), payments to be made to warrant holders, changes in Innovus liabilities and working capital, and other adjustments. This initial consideration to Innovus common shareholders is currently estimated to consist of approximately 3.9 million shares of Aytu stock. Each Innovus common shareholder will also receive contingent value rights ("CVRs"), representing the right to receive additional consideration of up to an aggregate of $16 million, paid for in cash or stock at Aytu's option, over the next five years if certain revenue and profitability milestones are achieved.

Innovus generated nearly $23 million in revenue during the twelve-month period ended September 30, 2019.

Through this combined entity, Aytu will expand into the $40 billion consumer healthcare market with a portfolio of over thirty-five consumer products competing in large therapeutic categories including diabetes, men's health, sexual wellness and respiratory health. This expanded product line broadens Aytu's portfolio beyond prescription therapeutics to enable wider revenue distribution, reduced seasonality associated with Aytu's seasonal antitussive product line, and higher revenue from an expanded base of proprietary products.

Combined, Aytu and Innovus generated approximately $43 million in revenue over the twelve-month period ended September 30, 2019. The companies believe this business combination will provide increased revenue scale and enable operational synergies that can be leveraged to accelerate the combined company's growth and path to profitability. Aytu will also take over the outstanding notes payable of Innovus which, at the time of signing, was approximately $2.8 million.

Upon closing, Aytu expects to operate the commercial aspects of the Innovus consumer business separately from Aytu's prescription business, while rationalizing general and administrative expenses through the removal of Innovus' public company costs and redundant administrative and operational processes, along with the reduction in overhead, administrative and facilities costs.

Aytu's prescription product portfolio will continue to be primarily commercialized through the existing Aytu sales force, while the consumer health products will continue to be primarily commercialized via Innovus' proprietary Beyond Human marketing platform. However, both lines of business are expected to benefit from opportunistic cross-selling such that some consumer products may be marketed in the physician office setting by Aytu's sales force, while the marketing of the prescription products may be bolstered through various online and direct-to-consumer marketing initiatives.

The boards of directors of both companies have approved the terms of the merger transaction, which is subject to the approval of both companies' shareholders. At the time of signing the definitive agreement, Aytu had collected voting agreements supporting the merger transaction that represent approximately 35% of current shares outstanding. Innovus has thus far collected voting agreements supporting the transaction that represent approximately 24% of shares outstanding.

Story continues

The transaction, which is expected to close on or around March 31, 2020, pending timing of review by the Securities and Exchange Commission and a shareholder vote, which would follow the effectiveness of the S-4/proxy statement. The merger is subject to customary closing conditions and regulatory approvals.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharmaceuticals is an emerging over the counter ("OTC") consumer goods and specialty pharmaceutical company commercializing, licensing and developing safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality. The Company is dedicated to being a leader in developing and marketing new OTC medicines and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription to OTC.

No Offer or Solicitation

Communications in this news release do not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction or otherwise, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Communications in this news release do not constitute a notice of redemption with respect to or an offer to purchase or sell (or the solicitation of an offer to purchase or sell) any security of Innovus.

Additional Information and Where to Find It

In connection with the proposed transaction between Aytu and Innovus, Aytu and Innovus will file relevant materials with the Securities and Exchange Commission (the "SEC"), including an Aytu registration statement on Form S-4 that will include a joint proxy statement of Aytu and Innovus that also constitutes a prospectus of Aytu, and a definitive joint proxy statement/prospectus will be mailed to shareholders of Aytu and Innovus. INVESTORS AND SECURITY HOLDERS OF AYTU AND INNOVUS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by Aytu or Innovus through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Aytu will be available free of charge on Aytu's internet website at https://irdirect.net/AYTU under the heading "SEC Filings" or by contacting Aytu's investor relations contacts at (646) 755-7412 or james@haydenir.com. Copies of the documents filed with the SEC by Innovus will be available free of charge on Innovus' internet website at https://innovuspharma.com/Investors/ under the heading "SEC Filings" or by contacting Innovus' investor relations at ir@innovuspharma.com.

Certain Information Regarding Participants

Aytu, Innovus, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Aytu is set forth in its Annual Report on Form 10-K for the year ended June 30, 2019, which was filed with the SEC on September 26, 2019. Information about the directors and executive officers of Innovus is set forth in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on April 1, 2019 and its proxy statement for its 2019 annual meeting of shareholders, which was filed with the SEC on April 30, 2019. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at http://www.sec.gov and from Investor Relations at Aytu or Innovus as described below.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements, including but not limited to any statements regarding the expected timetable for completing the proposed transaction, the results, effects, benefits and synergies of the proposed transaction, future opportunities for the combined company, future financial performance and condition, guidance and any other statements regarding Aytu's or Innovus' future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: failure to obtain the required votes of Innovus' shareholders or Aytu's shareholders to approve the transaction and related matters, the risk that a condition to closing of the proposed transaction may not be satisfied, that either party may terminate the merger agreement or that the closing of the proposed transaction might be delayed or not occur at all, the price per share utilized in the formula for the initial $8 million merger consideration may not be reflective of the current market price of Aytu's common stock on the closing date, the failure to meet the revenue and profitability milestones that trigger the CVRs such that Innovus shareholders never realize value from the CVRs, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the transaction, the diversion of management time on transaction-related issues, the ultimate timing, outcome and results of integrating the operations of Aytu and Innovus, the effects of the business combination of Aytu and Innovus, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, regulatory approval of the transaction, risks relating to gaining market acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for AYTU Investors:

James CarbonaraHayden IR(646)-755-7412james@haydenir.com

Contact for INNV Investors:

Randy BerholtzInnovus Investor Relations(858) 249-7865ir@innovuspharma.com

SOURCE: Aytu BioScience, Inc.

View source version on accesswire.com: https://www.accesswire.com/571135/Aytu-BioScience-and-Innovus-Pharmaceuticals-Announce-Filing-of-Form-S-4-Registration-Statement-Related-to-Proposed-Acquisition-of-Innovus-by-Aytu-BioScience

More:
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu...

Waist Circumference Affects Coronary Plaque Accumulation in Testosterone Therapy – Endocrinology Advisor

Older men receiving testosterone treatment with higher waist-to-hip ratio (WHR) experience greater increases in noncalcified coronary plaque volume, according to study results published in The Journal of Clinical Endocrinology & Metabolism.

Several studies have explored the effect of testosterone treatment on cardiovascular risk, reporting conflicting results. The Testosterone Trials included men aged 65 years with evidence of hypogonadism who were randomly assigned to placebo gel or testosterone 1% gel. The Cardiovascular Trial of the Testosterone Trials reported that in older men with hypogonadism, testosterone treatment was associated with greater progression of noncalcified plaque.

The goal of this study was to assess the impact of baseline anthropometric measures and cardiovascular biomarkers on the progression of coronary artery plaque volume in patients from this cardiovascular evaluation study of the Testosterone Trials.

The study included 170 patients, of whom 138 (mean age, 71.2 years) completed the study. Of these, 73 received testosterone treatment (average body mass index, 30.63.8 kg/m2; mean WHR, 1.0) and 65 received placebo (average body mass index, 30.53.5 kg/m2; mean WHR, 1.0).

Of various anthropometric measures and cardiovascular biomarkers evaluated for possible correlations with the progression of coronary artery plaque volume, the only significant interaction was between treatment assignment and WHR in the testosterone group (P =.007).

The model used in the study indicated that for every 0.1 change in WHR (baseline WHR value range, 0.9-1.2), 12-month treatment with testosterone was associated with an increase of 26.96 mm3 (95% CI, 7.72-46.20 mm3) in noncalcified plaque volume.

The researchers noted several study limitations, including the use of a surrogate marker and not a clinical outcome to measure heart disease, as well as limiting the study population to elderly men with low testosterone levels. As such, the results may not apply to other populations.

[A]mong older men receiving testosterone treatment, those with higher vs. lower WHR may experience greater increases in noncalcified coronary plaque volume, concluded the researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Follow @EndoAdvisor

Reference

Shaikh K, Ellenberg SS, Nakanishi R, et al. Biomarkers and non-calcified coronary artery plaque progression in older men treated with testosterone [published online November 30, 2019]. J Clin Endocrinol Metab. doi:10.1210/clinem/dgz242

Read this article:
Waist Circumference Affects Coronary Plaque Accumulation in Testosterone Therapy - Endocrinology Advisor

Ascending Demand for Male Hypogonadism to Propel the Growth of the Male Hypogonadism Market Between 2018 – 2028 – Markets Gazette 24

TMRR in its latest research report states that the global market size of Male Hypogonadism market was $XX million in 2018 with XX CAGR from 2014 to 2018, and is expected to reach $XX million by the end of 2029 with a CAGR of XX% from 2019 to 2029.

Global Male Hypogonadism Market Report 2019 Market Size, Share, Price, Trend and Forecast is an intuitive and exhaustive study on the current and future prospects of the global Male Hypogonadism industry. The key insights are elucidated as under:

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1127&source=atm

There are 4 key segments covered in this report: machine segment, product type segment, end use segment and regional segment.

Competitive landscape of Male Hypogonadism market has tier 1, tier 2 and tier 3 players and provides a dashboard view of their strategies and intensity mapping.

Trends and Opportunities

The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the markets growth.

However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lipral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the markets growth.

Global Male Hypogonadism Market: Regional Overview

The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe.

Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism.

Major Companies Mentioned in Report

Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring.

Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1127&source=atm

For regional segment, the following regions in the Male Hypogonadism market have been covered

Reasons to Purchase this Report:

We also can offer customized report to fulfil special requirements of our clients. Regional and Countries report can be provided as well.

Reports are available at concessionary rates. Hurry to avail offer!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1127&source=atm

See the rest here:
Ascending Demand for Male Hypogonadism to Propel the Growth of the Male Hypogonadism Market Between 2018 - 2028 - Markets Gazette 24

Male Hypogonadism Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 – Exponent Online

The Global Male Hypogonadism Market Outlook Report is a comprehensive study of the Male Hypogonadism industry and its future prospects.. The Male Hypogonadism market accounted for $XX million in 2018, and is expected to reach $XX million by 2024, registering a CAGR of YY% from 2019 to 2024.

Lack of sex hormones, generally referred to male hypogonadism, results into several health risks such as osteoporosis and heart disease, owing to thinning of bones. The global market for male hypogonadism comprises several patented brands with high market penetration. Growth in geriatric population along with rising incidences of rheumatoid arthritis and obesity are primary factors influencing prevalence of male hypogonadism.Read Report Details at https://www.proaxivereports.com/10480

List of key players profiled in the Male Hypogonadism market research report:

Endo International Plc, Eli Lilly and Company Ltd., AbbVie, Inc., Pfizer, Inc., Merck KGaA, Allergan Plc, Sun Pharmaceutical Industries Limited, Ferring B.V.

By TherapyTestosterone Replacement Therapy, Gonadotropin Replacement Therapy ,

By Drug TypeTopical Gels, Injectables, Transdermal Patches, Others ,

By Disease TypeKlinefelters Syndrome, Pituitary Adenomas, Kallmann Syndrome, Other Types ,

By

By

By

Request for Sample Report athttps://www.proaxivereports.com/request-sample/10480

The global Male Hypogonadism market is segmented based on product, end user, and region.

Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and, rest of Asia-Pacific) and EMEA (Brazil, South Africa, Saudi Arabia, UAE, rest of EMEA).

Ask more details or request custom reports to our experts athttps://www.proaxivereports.com/pre-order/10480

Moreover, other factors that contribute toward the growth of the Male Hypogonadism market include favorable government initiatives related to the use of Male Hypogonadism. On the contrary, high growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

Key Benefits for Stakeholders from Male Hypogonadism Market Report:

This report entails a detailed quantitative analysis along with the current global Male Hypogonadism market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.The Male Hypogonadism market size and estimations are based on a comprehensive analysis of key developments in the industry.A qualitative analysis based on innovative products facilitates strategic business planning.The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the Male Hypogonadism industry.

Purchase Male Hypogonadism Market Report athttps://www.proaxivereports.com/checkout/10480

Read more here:
Male Hypogonadism Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 - Exponent Online

Men who receive testosterone therapy nearly twice as likely to develop blood clots, researchers find – Minnesota Daily

Men are nearly two times more likely to develop blood clots while undergoing testosterone therapy, according to University of Minnesota research.

The study, which was published last month, found that men on testosterone therapy were at a heightened risk of developing a condition commonly known as VTE. With this condition, blood clots form in the veins and travel to the lungs, potentially blocking the blood supply. Men seek testosterone therapy for a variety of reasons, including low testosterone levels and sexual dysfunction.

These findings were shown in both men with and without hypogonadism, a condition where the body does not produce enough testosterone naturally.

There hasnt really been [this] kind of care given to a hypogonadism diagnosis. A lot of other studies either control for it or restrict it to one specific group of men, said Robert Walker, the study's lead and a research assistant at the Universitys Minnesota Population Center.

In the study, researchers separated men with the condition and men without it. By doing so, they were able to see a near doubling of risk in both groups, he said. They were also able to control for factors such as smoking status, obesity and race.

Overall for Americans, there [are] about 1 million cases of VTE annually, Walker said, which includes a lifetime risk of one in 12 people. Symptoms include leg pain, swelling and rashes.

While men typically receive testosterone therapy for hypogonadism, they may also seek it for unwanted weight gain or emotional regulation.

"These findings are important, particularly for the men with no hypogonadism, as they suggest that off-label testosterone use for symptoms of 'male menopause' may be causing harm, said Pamela Lutsey, a co-author of the study and University associate professor in the Division of Epidemiology and Community Health, in an email to the Minnesota Daily.

When men seek testosterone therapy for reasons other than hypogonadism, there is not necessarily an official diagnosis. However, treatment could fix those symptoms, Walker said.

Testosterone therapy is more than just a kind of stroke and heart failure risk factor, we have to take into account other cardiovascular symptoms, he said.

In the future, the researchers can use the same study design to test the effects of testosterone therapy on women, Walker said.

Women who need to take testosterone for one reason or another may also be put at a risk, he said.

Women are often at risk of developing VTE while pregnant because of the pressure on their organs or afterward in the postpartum period, Walker said.

An important next step is for other researchers to reproduce these results, said Richard MacLehose, another co-author of the study and University associate professor in the Division of Epidemiology and Community Health.

Walker said he began this study because of the lack of research papers on the effects of testosterone therapy.

The story of the paper is really just to think before you prescribe, he said.

View post:
Men who receive testosterone therapy nearly twice as likely to develop blood clots, researchers find - Minnesota Daily

Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO (testosterone undecanoate) Capsules CIII – GlobeNewswire

NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to the team. Together they strengthen the companys commercialization capability for JATENZO (testosterone undecanoate) capsules, the first-in-class oral testosterone replacement therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypogonadism. See indication and important risk information, including boxed warning below.

Dr. Newmark, Mr. Jaeger, Mr. Rodriguez, Ms. Wright and Mr. Holloway join a management team led by Robert Dudley, Ph.D., Clarus Therapeutics Chief Executive Officer and co-inventor of JATENZO. Dr. Dudleys legacy in mens health includes CEO leadership of the company that developed and launched AndroGel, a product he co-invented and the last major advancement in testosterone replacement therapy delivery.

We are proud to bring Jay, Frank, Jose, LaTonya, and James into an organization that shares their focus on innovation and excellence. They have each demonstrated an ability to connect with medical professionals who are invested in mens health, said Dudley. Their expertise will help us make the long sought-after oral testosterone option widely available to appropriate hypogonadal men.

INDICATION

JATENZO (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Limitation of use

Safety and efficacy of JATENZO in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASES IN BLOOD PRESSURE

CONTRAINDICATIONS

JATENZO is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, in women who are pregnant, in men with a known hypersensitivity to JATENZO or its ingredients, or in men with hypogonadal conditions that are not associated with structural or genetic etiologies as JATENZO has not been established for these conditions and there is a risk of increased blood pressure with JATENZO that can increase the risk of MACE.

WARNINGS AND PRECAUTIONS

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence 2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

The safety and efficacy of JATENZO in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing JATENZO to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. There is insufficient long-term safety data in geriatric patients utilizing JATENZO to assess the potentially increased risk of cardiovascular disease and prostate cancer.

Please see accompanying full Prescribing Information, including BOXED WARNING on increases in blood pressure.About JATENZO JATENZO is a first-in-class proprietary oral soft gel formulation of testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

JATENZOs proprietary formulation is built around testosterone undecanoate a testosterone prodrug that the body converts to testosterone. In the JATENZO pivotal inTUne (investigation of its oralTestosteroneUndecanoate) clinical trial, 87% (n=222) of men treated with JATENZO achieved average circulating levels of testosterone in the normal range for men.

About Clarus Therapeutics, Inc.Clarus is a men's specialty pharmaceutical company developing and preparing for the commercial launch of JATENZO, a product protected by patents issued in the United States and in other major pharmaceutical markets around the world. Clarus owns the worldwide, royalty-free commercialization rights for JATENZO.For more information, please visit:www.clarustherapeutics.com.

Media ContactAmir KhanPhone: (212) 462-8767Email: Amir.Khan@Syneoshealth.com

2019 Clarus Therapeutics, Inc. All rights reserved.

Visit link:
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO (testosterone undecanoate) Capsules CIII - GlobeNewswire

Get To Know Hosanna Plath, The ‘Welcome To Plathville’ Star And Accomplished Violinist – YourTango

She only appeared in the pilot!

Who is Hosanna Plath? That's been the question on everybody's mind since Welcome to Plathvilledebuted on TLC, the network that once focused on things like childbirth and dinosaur bones, but now focuses on messy relationships, hypogonadism, multiple birth families, and metabolic issues with their accompanying bariatric procedures. So what makes Hosanna Plath stand out from the rest of the Plath clan?

RELATED:Meet The 9-Kid, No-Technology Plath Family Featured In New TLC Show 'Welcome To Plathville'

Welcome to Plathvilleis the latest TLC reality show that focuses on a family that most would consider "strange and unusual." The Plath family led by matriarch Kim and patriarch Barry say on the show they are "devout Christians," and though they don't get into detail about which denomination of Christianity they follow, there are some photos of the family posing in front of a Baptist church. What makes them remarkable, however, is not their adherence to Christianity, but their practice of isolating their children from pop culture. In many of the previews for the show, for example, viewers are left to marvel as the Plath children Hosanna included are left to wonder who people like Justin Bieber and Tom Brady really are.

That said, though the family has no exposure to pop culture, they do have a YouTube channel that promotes their gospel music. Each family member plays an instrument, so let's look at the violinist, Hosanna Plath.

Though Hosanna Plath has an older brother, Ethan who is the officialoldest of the Plath children she's the oldest Plath daughter. She is one of 9 children and would have been one of 10 had her younger brother, Joshua, not been killed in a tragic accident.

Hosanna Plath is known, in her family band, for playing the violin. She's an accomplished violinist and actually turned down going to college to continue to play the violin. (Since she married her husband, Timothy Noble, she's also played as a duet with him.)

In theWelcome to Plathvillepilot, it was revealed that Hosanna Plath had a musical scholarship to college, but turned it down to continue to play with the family band. This decision drew some fire from the fandom, especially since it was later revealed that Kim Plath the matriarch of the family graduated from FSU.

RELATED:Meet Nail Artist Lexi Martone Star Of The New TLC Reality Series 'Unpolished'

In 2016, Hosanna Plath went to the National Quartet Convention. And it was there that she met Timothy Noble, the man who would become her husband. Noble plays piano, and he often plays together with his wife as a duet. They dated for two years before they ultimately got married in June 2019.

According to reports, there'stension within the family because Hosanna Plath was considered the "musical prodigy" of the family. Because she's so talented and accomplished, Hosanna Plath reportedly taught her siblings how to play their respective instruments. So when Hosanna married Timothy and the duo moved to Ohio thus, away from the family the Plath family band seemed to languish. As such, rumors began circulating that there was a fracture in the Plath family.

Sometimes, it really is the devil you know. While therecertainl, is no shortage of people who criticize the Plath family for raising their children including Hosanna Plath so strictly, there are some good reasons for their method. As revealed on the show, Kim Plath drew a hard line against having alcohol served at her son, Ethan's, wedding, because she admitted she was a recovering alcoholic. Her biggest fear, she said, was that her children would walk down the same path that she walked down.

While, no doubt, that is a bit extreme, we can certainly understand the desire to protect your children. We look forward to hearing more from Hosanna Plath in the future.

RELATED:Meet Kim Plath Controversial Matriarch Of Family Raising 9 Kids Technology-Free On TLC's 'Welcome To Plathville'

Bernadette Giacomazzo is an editor, writer, and photographer whose work has appeared in Teen Vogue, People, Us Weekly, The Source, XXL, HipHopDX, The Los Angeles Times, The New York Post, BET.com, and more. She is also the author of The Uprising series and is the CEO of the acclaimed G-Force Marketing & Publicity firm, which has been featured in The Hollywood Reporter and has scored film, television, radio, and print placements for celebrity clientele worldwide.

Here is the original post:
Get To Know Hosanna Plath, The 'Welcome To Plathville' Star And Accomplished Violinist - YourTango

Global Hormone Replacement Therapy Market is Anticipated to Reach US $17.4 Billion by the End of 2025 – The Chestnut Post

This post was originally published on this site

Press Release updated: Dec 11, 2019 15:00 EST

LOS ANGELES, December 11, 2019 (Newswire.com) QY Research has lately come up with a new report titled, Global Hormone Replacement Therapy Market Report, History and Forecast 2014-2025, for the projected period of six years, i.e. between 2019 and 2025. The reports states that the global Hormone Replacement Therapy market was valued at US $15.7 billion in 2018 and is expected to reach US $17.4 billion by the end of 2025. The global market is anticipated to register a sluggish CAGR of 1.5% from 2019 to 2025.

Request a Sample Copy of this Report athttps://www.qyresearch.com/sample-form/form/1123650/global-hormone-replacement-therapy-market

Factors Hampering the Growth of the Global Hormone Replacement Therapy Market

Medical Conditions and Healthcare:Lack of awareness amongst patients regarding hormone deficiencies and imbalances, resulting in serious conditions such as menopause and hypothyroidism, is expected to hamper the growth of the market.

Drugs and Pharmaceuticals:Lack of drug delivery systems, particularly in developing economies and the high cost of therapies and potential side effects are anticipated to restrain the growth of the market.

Risk of Cancer and Heart Disease:Uncertainty among doctors for prescribing Hormone Replacement Therapy due to the risk of heart disease and breast cancers is likely to obstruct the growth of the market.

Availability of Alternate Options A Significant Factor Obstructing Growth

The type segment is further sub-segmented into growth hormone, Estrogen Hormone, Testosterone Hormone, and thyroid hormone. Based on application, the segment is bifurcated into

Due to premature birth resulting in underdevelopment in infants, treatments for growth hormone deficiency has witnessed considerable demand over the years. Increasing awareness among women regarding menopause is likely to boost the growth of the application segment. However, the availability of alternative options in the market, along with the presence of various brands and generic drugs, are likely to impede the growth of the market.

Prevalence of Hormone Related Diseases Likely to foster Regional Market

The global market is bifurcated into Asia-Pacific, Europe, North America, Central America, Middle-east, and Africa. Asia-Pacific is likely to hold a considerable share of the market due to the presence of a huge population and an increase in the prevalence of conditions such as hypothyroidism, menopause, hypogonadism, and hormone deficiency.

Innovation and Product Development A Major Emphasis of Key Players

Some of the top players operating in the market are Pfizer, Eli Lilly, Novo Nordisk, AbbVie, Merck, Bayer, KGaA, Mylan, Novartis, Teva, Abbott, Roche, Ipsen, Endo International, TherapeuticsMD, and ANI Pharmaceuticals. Top players of the market are inclined to incorporate advanced technology and to collaborate for offering innovative products.

Get a Complete Report in your Inbox within 24 hours (USD 2,900): https://www.qyresearch.com/settlement/pre/a2424e7155d3f73613318581f3c173c7,0,1,Global-Hormone-Replacement-Therapy-Market-Report-History-and-Forecast-Breakdown-Data-by-Companies-Key-Regions-Types-and-Applicatio

Source: QY Research, Inc.

The rest is here:
Global Hormone Replacement Therapy Market is Anticipated to Reach US $17.4 Billion by the End of 2025 - The Chestnut Post

Erectile dysfunction: When he’s (not) in the mood for love – AsiaOne

Men are often portrayed as wanting to have sex all the time. In reality, a sluggish sex drive is something many men deal with at some point in their lives.

Several studies, including the often-cited Massachusetts Male Ageing Study from the University of Boston (conducted between 1987 and 1989), suggest erectile dysfunction affects more than half of all men to some degree, and is more prevalent in older men.

A low libido does not just take a toll on a man's emotional well-being; it can affect his partner and relationship, too, says Dr Angela Tan, a Singapore-based family doctor and intimacy coach.

"For starters, your male partner may feel that he is not satisfying you, and this may make him feel inadequate. It may also affect his identity and how he sees himself as a man. And if your once fulfilling sex life is now non-existent or no longer making you happy, you may wonder if [he] is attracted to you any more. This may create problems like anger and resentment, and may even lead to arguments and affairs later."

To help your partner and prevent misunderstandings, it is useful to know what may be affecting his libido.

According to Dr Colin Teo Chang Peng, a urologist at Colin Teo Urology in Singapore, one of the top causes of a low libido in men is low testosterone.

This is sometimes referred to as andropause or male "manopause", testosterone deficiency syndrome (TDS) or late onset hypogonadism (LOH).

"A man's testosterone levels start to decrease at a rate of about one per cent to two per cent every year from the age of 40," Teo explains.

"While testosterone is essential to sexual health and libido, it is also a metabolic hormone that has an effect on a man's blood-sugar control, cardiac health, psychological well-being, motivational drive, memory and physical fitness."

Low testosterone is also commonly linked with other medical conditions such as diabetes, hypertension, metabolic syndrome, coronary heart disease, obesity and renal failure, he adds.

An online survey of more than 5,000 men revealed that male sexual desire is complex and cannot be reduced to a single equation.

The researchers behind the European survey found that low confidence in their ability to achieve and maintain an erection, a lack of attraction to their partner, and being in a long-term relationship were some of the factors associated with the respondents' low sex drive. The results were published in 2014 in medical journal The Journal of Sexual Medicine.

There may be other reasons your partner cannot get in the mood for sex. Tan says that these may be medical - brain conditions like stroke, for instance; conditions that require chemotherapy, like cancer, which may deflate him emotionally; and liver problems that can cause hormonal issues.

Depression and anxiety disorder are also known to be mood killers.

If your partner is on medication, for instance some types of antidepressants and antipsychotics, he may experience a low libido, too. Even alcohol can decrease his sexual desire.

"Other causes may be related to your man's lifestyle - he may be stressed at work or under financial stress, for example; or perhaps his relationship with you feels strained, and that is affecting his desire to have sex with you," Tan says.

"Some men also have certain cultural or religious beliefs and values that may influence their views on sex, which may in turn dampen their libido."

Many men feel uneasy discussing their lack of sexual desire, especially in Asian societies, where talking about sex is considered taboo. However, Teo believes that this is slowly changing, with more men seeking their doctors' advice.

"The culture seems to be a bit more open now," he says. "More patients and doctors are aware that many sexual problems are also medical conditions. They also know that these conditions can be treated safely and effectively. We do see more men consulting their doctors about low libido and other andropause symptoms like lethargy, and many of these patients are accompanied by their partners."

The men who seek Teo's advice as soon as they notice symptoms tend to be in their 40s and 50s, leading fast-paced lives at or near the peak of their careers. A decline in their work, fitness or sexual performance is usually what motivates them to look for solutions to help restore their quality of life.

Patients who do not have fast-paced, active or career-driven lives may not notice the effects of andropause straight away and often take a while to ask their doctor for help.

It is not easy broaching the subject of low sex drive with your man, but you should not sweep the issue under the carpet, either. Tan suggests communicating your concerns in a calm, positive and non-threatening manner.

"Communication is key in this kind of situation," Tan says. "You want to be honest but not rude, and what you should not do is blame your partner or yourself, as this can have a detrimental effect on your relationship as well as your and your man's emotional well-being."

Tan advises couples to get professional help to determine the cause of a man's low sex drive and then explore ways to solve it together.

In the meantime, she says it is still possible to be intimate and maintain your physical and emotional connection, by cuddling and engaging in oral sex. Your man can also satisfy you using sex toys.

Fortunately, there are many solutions to help men get their sex lives back on track. Teo says that when a patient complains about andropause symptoms and his testosterone levels are found to be below normal, he is diagnosed with TDS and advised to begin testosterone replacement therapy (TRT).

Safe and effective, this treatment can be delivered orally with capsules, through the skin with daily gel applications, or as an injection every three months.

If the patient also has a chronic medical condition, he will be advised to undergo treatment for it, as the condition may impact his libido.

"Once testosterone levels are restored, other sexual dysfunctions can be actively remedied," says Teo. "These include erectile dysfunction, which can be treated with erectogenic medications in the form of oral tablets, injectables, and the recently available low-intensity shock wave therapy [LIST]."

In LIST, a wand-like device delivers mild shock waves to the penis that assists in the growth of new blood vessels.

Teo adds that, for patients with premature ejaculation, oral medications can help, giving the patient better control and helping the couple achieve satisfaction during sex.

In cases that do not respond to drugs or other therapies, penile implant surgery is a popular option.

A holistic approach is key when addressing low libido, so it may be necessary to include other forms of treatment, such as psychotherapy and couples' counselling.

Ultimately, while all forms of sexual dysfunction can be treated, Teo says a healthy lifestyle goes a long way towards helping men enjoy a satisfying sexual relationship.

"Exercising regularly relaxes the body and triggers the release of feel-good chemicals called endorphins, which boost your emotional well-being, while eating wholesome foods can counter some of the symptoms of andropause. You should also keep any chronic medical conditions in check and work towards strengthening your relationship with your partner."

This article was first published inSouth China Morning Post.

See the original post:
Erectile dysfunction: When he's (not) in the mood for love - AsiaOne

Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational – Financial Post

TORONTO Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the revised commercial partnership agreement with Aytu Bioscience (Aytu) to accelerate the growth of NATESTO in the United States is now closed and fully effective as of December 1, 2019. Both parties have mutually waived the closing conditions of the revised partnership agreement, including the requirement that Acerus complete a raise of a minimum of USD 10 million on or before the end of January 2020, enabling Acerus to launch a U.S.-based specialty sales force, which will promote NATESTO to urologists and endocrinologists. Aytu will continue to book all NATESTO revenue in the United States and they will promote NATESTO to all other specialties including internal medicine and family practice.

To accelerate the launch of Acerus U.S. commercial team, Aytu has agreed to transfer 5 current sales personnel to Acerus as of December 2, 2019. These staff will operate as Acerus employees but they will remain on Aytus payroll until the earlier of the date on which Acerus is ready to fully assume the personnel or June 30, 2020. Aytu will deduct the costs of these sales personnel from quarterly payments otherwise owed to Acerus under the revised agreement, with a final accounting to be done once per year. Throughout 2020, Acerus will be building out a complete US-based specialty care sales force and other commercial functions, significantly increasing the number of employees working directly on NATESTO in the United States.

This co-promotion is expected to significantly increase sales force coverage of targeted U.S. prescribers, putting a higher promotional focus on urologists and endocrinologists, while enabling Aytu to focus its promotional efforts in primary care and other specialties.

Acerus is extremely pleased to see our revised partnership with Aytu moving to execution mode as we strongly believe that the performance of NATESTO in the U.S. will benefit from an enhanced commercial focus on urology and endocrinology, said Ed Gudaitis, President and Chief Executive Officer of Acerus. We are happy to welcome the former Aytu staff to the Acerus team. With this revised partnership, Acerus is effectively pivoting its focus of effort to the U.S. NATESTO opportunity. As such, we have implemented a resource reallocation program within our Canadian office that has led to a greater than 50% reduction in headcount so that we can align our SG&A spend appropriately.

On July 29, 2019 the companies agreed to expand their commercial partnership and amend and restate the original 2016 NATESTO exclusive U.S. license agreement. Under the terms of the new agreement, Aytu returns the NDA for NATESTO in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel). Aytu will retain its primary care sales force (Aytu Sales Channel) and will continue to book all product net revenue while serving as the exclusive U.S. supplier of NATESTO to wholesalers, pharmacies and other customers that receive a direct shipment. Financial payments will be based upon a tiered level of net revenue, post cost of goods sold (COGS), based on annual sales performance in the respective Acerus and Aytu Sales Channels.

To establish a high performing commercial footprint in the U.S., Acerus has engaged Syneos Health (NASDAQ: SYNH), a leading integrated biopharmaceutical solutions organization including the industrys largest Contract Commercial Organization (CCO), to be its commercialization partner. Syneos Health has extensive experience in Mens Health and with NATESTO, and offers an end-to-end model that will enable Acerus to rapidly stand up a U.S. commercial team; to scale across all aspects of commercialization, including medical and regulatory affairs, managed markets, marketing and sales; and will provide greater flexibility and effectiveness in resource deployment.

Low testosterone is estimated to affect approximately 39% of men over 45 years old in the U.S.; however, because the condition is underdiagnosed the overall prevalence is uncertain1. While patients have access to other treatment options, NATESTO is unique in that it is administered in seconds via a convenient and simple nasal gel applicator, addressing the risk of testosterone transference associated with other topical products, which carry black box warnings on their product labels.

About NATESTO (Testosterone) Nasal Gel

NATESTO is a nasal gel formulation of testosterone developed by Acerus Pharmaceutical Corporation and indicated as a replacement therapy for men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). It is the first and only nasally-administered testosterone product approved by the U.S. Food and Drug Administration, Health Canada and South Korea Ministry of Food and Drug Safety (MFDS), available in a no-touch dispenser with a metered dose pump. A copy of the NATESTO Canadian product monograph can be found at: http://www.aceruspharma.com/English/products-and-pipeline/NATESTO /default.aspx. For further information, specific to the U.S. product dosing and administration, please visit: http://www.NATESTO .com.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of mens health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Acerus shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit http://www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO in the United States, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 which is available at http://www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

1 Mulligan T, Frick MF, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul 1; 60(7): 762769

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005215/en/

Contacts

Media: Edward Gudaitis President and Chief Executive Officer egudaitis@aceruspharma.com (905) 817-8194

Go here to see the original:
Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational - Financial Post

Testosterone Replacement Therapy Market to Expand at a Robust 4.20% CAGR Between 2016 and 2024 – Montana Ledger

In a recent report by Transparency Market Research, it is shown that the global testosterone replacement therapy market is expected to grow negatively in the forecast period of 2016 to 2024. This adverse growth of the market is the result of various bans on the use of testosterones by various governments across the globe. Moreover, stringent regulations are also forcing company back-outs from the global testosterone replacement therapy market. This is also adding to the negative growth of the market.

Report Overview @

https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html

The Market to Experience -4.2%CAGR During the Forecast

According to the report, the global testosterone replacement therapy market is expected to generate substantially less revenue than previous forecast period. In terms of revenue, the global testosterone replacement therapy market is expected to reach to the value of US$1.3 bn during the forecast of 2016 to 2024.

The global testosterone replacement therapy market is expected to experience 4.2% CAGR. This sluggish growth of the market is the result of various bans on the drugs that are used in the therapy.

Moreover, considering the adverse effects of the testosterone replacement therapy, governments of various countries have posed stringent regulations on their application. This is yet another factor that is compelling the global testosterone replacement therapy market to grow negatively during the forecast.

Historical analysis of the global testosterone replacement therapy market by experts at Transparency Market Research shows that the market stood US$ 2.0bn at the end of 2015.

Request Sample @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

AbbVie, INC. to Account for Majority of Market Share

According to the report, the global testosterone replacement therapy market is predominantly consolidated. This is because majority of the dynamics of the market is dominated by AbbVie, INC. a U.S. based pharmaceutical company that specializes in testosterone replacement therapy drugs. This dominance by the company and overall sluggish growth is making the new players entry quite difficult in testosterone replacement therapy market.

These players are looking forward to adopt various strategies such as mergers, collaborations, and partnerships in order to have a stable future in the global crop maintenance robots market. These strategies are providing the businesses with required resources to compete against the well established players of the market.

Whereas, AbbVie, INC. is launching new products in order to maintain its dominance in the global testosterone replacement therapy drugs market. Recently, the company had applied for approval of its cream product that can be used externally for testosterone replacement therapy.

Rising Cases Hypogonadism to Show Some Sign of Growth for the Markets

According to various research and studies, the number of hypogonadism has risen substantially over couple of decades. This growth of the condition is showing some signs of growth in global testosterone replacement therapy market. Rising geriatric population is another minor factor that is expected to show growth possibilities in global testosterone replacement therapy market. Furthermore, various campaigns to educate people about the benefits of testosterone is also helping the global testosterone replacement therapy market to grow slowly in recent times.

Request Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

North America is Expected to Exhibit Maximum Growth in the Market

Geriatric population in countries such as U.S. and Canada is one of the major reasons that are supporting North America to dominate the regions of global testosterone replacement therapy market. The growth of the region is also attributed to the presence of various key players of global testosterone replacement therapy market.

The article is listed by Transparency Market Research titled Testosterone Replacement Therapy Market (Product Creams/Gels, Patches, Injections, Gums/Buccal Adhesives, Implants; Active Ingredient Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Testosterone Cypionate) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 2024.

Here is the original post:
Testosterone Replacement Therapy Market to Expand at a Robust 4.20% CAGR Between 2016 and 2024 - Montana Ledger

Human Chorionic Gonadotropin (HCG) Market 2019 By Share, Size, industry Trends, Outlook, Revenue, Manufacturers, Demand and Forecast to 2024 – Downey…

Human Chorionic Gonadotropin (HCG) Marketreport provides comprehensive insights, revenue generation information, and other significant information related to the global Human Chorionic Gonadotropin (HCG) market, as well as the different trends, drivers and restraints, opportunities, and threats in the parent market till 2024.

Rise in the incidence of male hypogonadism among the geriatric population is the key factor driving the market growth. In addition, increase in traction gained by hCG among healthcare professionals and patients would supplement the market growth. However, cautions and warnings issued by the FDA pertaining to the side effects of hCG therapy is expected to hamper the market growth. Moreover, untapped economies are set to offer lucrative opportunities for the expansion of the hCG market.

Get the Research Sample Copy @https://www.reporthive.com/enquiry.php?id=1989049&req_type=smpl

Key Players covered in this report:

Scrippslabs

Leebio

Kamiya Biomedical Company

Human chorionic gonadotropin (hCG) belongs to the family of gonadotropin hormones and is naturally produced by the placenta. hCG hormone plays a pivotal role after the formation of the embryo, and hence has gained significant traction over the years for the treatment of infertility in women and men. hCG triggers ovulation in women and assists in increasing the sperm count in men

Market by Type

-Subunit (-hCG)

-Subunit (-hCG)

Others

Market by Application

Research institutions

Pharmaceutical

Others

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a 5-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Get the Full Research Report @https://www.reporthive.com/checkout?currency=single-user-licence&reportid=1989049

Table of Contents

1 Executive Summary Market Attractiveness Analysis

1.1 Global Human Chorionic Gonadotropin (HCG) Market, by Product Type

1.2 Global Human Chorionic Gonadotropin (HCG) Market, by End User

1.3 Global Human Chorionic Gonadotropin (HCG) Market, by Region

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Market Structure

2.4 Key Buying Criteria

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 List of Assumptions

4 Market Dynamics

4.1 Introduction

4.1 Drivers

4.2. Integration of Advanced Technologies

4.3 Restraint

4.4 Opportunities

5 Market Factor Analysis

5.1 Supply Chain Analysis

5.2 Porters Five Forces Analysis

5.2.1 Threat of New Entrants

5.2.2 Bargaining Power of Suppliers

5.2.3 Threat of Substitutes

5.2.4 Bargaining Power of Buyers

5.2.5 Intensity of Rivalry

6 Market Channel

6.1 Overview

6.2 Store-Based

6.3 Non-Store-Based

7 Global Human Chorionic Gonadotropin (HCG) Market, by Product Type

8 Global Human Chorionic Gonadotropin (HCG) Market, by End User

9 Global Human Chorionic Gonadotropin (HCG) Market, by Region

Continued

About Us:

Report Hive Research delivers strategic market research reports, statistical survey, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, Individual and Start-ups, top management consulting firms, universities etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Get Healthcare & Life Science Market Research updates covering key companies like :Johnson & Johnson(NYSE: JNJ), Merck & Co., Inc.(NYSE: MRK), Eli Lilly And Co(NYSE: LLY), Bristol-Myers Squibb Co(NYSE: BMY), Cardinal Health Inc(NYSE: CAH), CVS Health Corp(NYSE: CVS), McKesson Corporation (NYSE: MCK), Amgen Inc (NASDAQ: AMGN), Abbott Laboratories (NYSE: ABT)

Report Hive Research

500, North Michigan Avenue,

Suite 6014

Chicago, IL 60611

United States

Website:www.reporthive.com

Email:[emailprotected]

Phone: +1 312-604-7084

More here:
Human Chorionic Gonadotropin (HCG) Market 2019 By Share, Size, industry Trends, Outlook, Revenue, Manufacturers, Demand and Forecast to 2024 - Downey...

Alex Nowbar’s weekly review22 November 2019 – The BMJ – The BMJ

Alex Nowbar reviews the latest research from the top medical journals

Annals of Internal Medicine

Coaching for weight maintenance

Conroy et al examine the role of coaching in weight management in a randomised controlled trial of 194 participants who had intentionally lost at least 5% of their body weight in the last two years. They also threw in a bit of electronic health records for good measure. The study arms were: tracking via electronic health records versus the same plus coaching. So really its a trial of a two year coaching programme. Good news, at two years weight regain in the coaching group was lower (2.1kg vs 4.9kg in the tracking only group). Those in the coaching group were more likely to maintain weight loss of at least 5%. The coaching was in the form of personalised health coaching through the electronic health record patient portal, with intensive initial contact (weekly for a month) that tapered off over the two years. The electronic health record served as an important part of the control for those in the tracking group because it was used to send the tracking participants questionnaires on general health. This was a well designed study of an interesting intervention format i.e. an electronic health record-based lifestyle intervention.

JAMA

Bempedoic acid for reducing LDL Cholesterol

If you name a trial CLEAR Wisdom, you should be prepared to be accused of being smug. But perhaps Esperion Therapeutics should be. Bempedoic acid was tested in a double-blind randomised controlled trial of 779 people with high cardiovascular risk and raised LDL-C despite maximally tolerated lipid-lowering therapy. At 12 weeks, it reduced LDL-C levels dramatically compared to placebo and was reasonably well-tolerated and safe. Its now ready for the next stage of clinical trials to establish the impact on cardiovascular outcomes. There are a number of players on this stage though, PCSK-9 inhibitors in particular. In fact there are a spate of new cardiovascular drugs making an appearance and each ones glory is being somewhat diluted by the others. It is therefore unclear which will become commonly prescribed and which will fall by the wayside. Unfortunately I suspect it will be marketing and trendiness that determines how this plays out because the head-to-head data is unlikely to come soon.

Lancet

Hope for NASH

Thyroid hormone analogue, resmetirom, is an oral drug for treatment of NASH fibrosis. Harrison et al tested it in a double-blind Phase 2 randomised controlled trial of 125 patients in the US. Naturally, drug-makers, Madrigal, were closely involved in this studys design and analysis. They found it reduced hepatic fat at 12 weeks as measured by MRI proton-density fat fraction. As well as singing the praises of this new drug, this study highlights the utility of this non-invasive measure of hepatic fat as opposed to biopsy which is not practical for serial monitoring. There were also significant lipid profile improvements with resmetirom compared to placebo. However all the efficacy outcomes assessed in this study were biomarkers not actual outcomes so the clinical benefits are not yet known. But these data are promising and certainly confirm that the thyroid hormone pathway has an important role in NASH fibrosis.

Steroids for the DIPs and PIPs

I hate to stereotype, but Dutch trials are often particularly robustly designed, like this double-blind randomised controlled trial of 6 weeks of prednisolone 10mg once daily versus placebo. The inclusion criteria are important here. Participants had to have symptomatic hand osteoarthritis with signs of inflammation in their distal and proximal interphalangeal joints. Objective evidence was required, including osteoarthritis nodes, swelling, or erythema and synovial thickening on ultrasound. And the inclusion criteria even went one step further to require finger pain of at least 30 mm on a 100-mm visual analogue scale (VAS) that flared up during a 48-h non-steroidal anti-inflammatory drug washout (defined as worsening of finger pain by at least 20 mm on the VAS). The primary endpoint of finger pain improvement on the VAS at 6 weeks was positive with a large effect size with no adverse safety signal. These data are extremely useful for those with this condition, but it sounds like itll be in the rheumatologists domain for now. The inclusion assessment appears too strict to be feasible in primary care.

JAMA Internal Medicine

Testosterone and thromboembolic risk

It seems obvious that testosterone therapy should be used only to treat hypogonadism and even then it should not be taken lightly. It has previously been linked to higher risk of heart attack or stroke. This large US observational study of men with deep vein thrombosis or pulmonary embolism (but without a cancer diagnosis) found an association between short-term testosterone therapy and increased risk of a thromboembolic event. The study design was interesting as each individual acted as their own control by examining them 6-12 months before the thromboembolic event while the 6 month period before the event was considered the case period. Other key findings were that thromboembolic risk was highest in the first 3 months after starting testosterone therapy, that route of testosterone made no difference to the risk and that the risk was present in men with or without hypogonadism.

NEJM

Apple watch rhythm notifications

Can an Apple watch detect atrial fibrillation? Probably. 419,297 young people participated in this study. They were monitored for a median of 117 days. An irregular rhythm was flagged in 0.52% of them (3% in the over 65s). These people got sent an ECG patch to wear for 7 days. Of those, only 21% returned the patch to the researchers. Of those who returned the patch, a third had documented atrial fibrillation. There is no comparator group to know whether the incidence of detected atrial fibrillation would have been similar without using the watch. And there was huge potential for selection bias, for example people who felt symptomatic might have been more likely to participate (so these data represent a skewed population) and people with more irregular rhythm periods and/or more symptoms might have been more likely to return the patch (again skewing the data). These bias issues are the reason studies arent conducted in this manner. This study design neither answers the question it says it set out to answer, nor provides clinically relevant evidence.

The new and improved smallpox vaccine

Pittman et al compared two doses of a new smallpox vaccine called modified vaccinia Ankara (MVA) to an existing vaccine (only requiring one dose) in an open-label randomised controlled trial of 440 people. They were looking for non-inferiority in peak antibody titres and the so-called take reaction which were both assessed in a blinded fashion. It is prudent but alarming that we are preparing our defences against a disease that has supposedly been eradicated. But there could be another outbreak one day. The existing vaccine is effective but carries fairly significant risks and hence the need for something better. MVA won the day with respect to equivalent efficacy and fewer serious adverse events. But do these efficacy endpoints (antibodies and the take) really reflect the protection this vaccine provides? And how long would the protection last? Who knows.

Colchicine after myocardial infarction

The inflammatory hypothesis in atherosclerosis has been bubbling away for many years. COLCOT is the first study that practically applies this with a degree of success. COLCOT was a double-blind randomised controlled trial of colchicine 500mcg once daily versus placebo for cardiovascular risk reduction after an MI. Colchicine started within 30 days of the MI was found to reduce cardiovascular events at 2 years, and surprisingly without substantially increasing diarrhoea rates. The cardiovascular event reduction was mainly driven by fewer strokes and fewer revascularisations for angina though which is a bit disappointing since MI and death prevention is what we were really hoping for. Colchicine for prevention of need for revascularisation doesnt even really make sense because there are plenty of other anti-anginal therapies. Arguably this event shouldnt have been part of the primary endpoint. Overall, there are benefits of colchicine that can justify its use but will patients really find it worth the hassle given all the other medications they get given (and often dont adhere to) after an MI?

Alex Nowbar is a clinical research fellow at Imperial College London

Read this article:
Alex Nowbar's weekly review22 November 2019 - The BMJ - The BMJ

Testosterone Replacement Therapy Market To Witness Huge Growth in 2024 – Downey Magazine

The globalmarket for testosterone replacement therapyis characterized by the presence of a large number of small and large scale manufacturers. All of the manufacturers have been steadfast in filling the meagre market gap in order to enhance their prospects of growth. Furthermore, research and development has been the central characteristic of al the market players operating in the global market.

In 2015, it was found that 80% of the total market share was held by the top five market vendors with AbbVie Inc. taking the lead. The large scale vendors are focusing on establishing an iconic brand for their product by resorting to rigorous marketing and advertising tactics. The smaller companies are expected to concentrate on capturing the local and regional markets to sustain themselves in the current scenario of stiff competition. A negative implication for the leading market players in recent times has been the loss of patents for their products. This has not only plundered them of revenues but has also affected the workflow of these companies.

Request a Sample to get Extensive Insights into theTestosterone Replacement Therapy Market

The market players are expected to launch awareness campaigns about testosterone replacement therapies in order to educate and inform the consumers. Hence, the market for testosterone replacement therapies is expected to witness the emergence of several new trends and opportunities over the forthcoming years. Some of the key players in the global testosterone replacement therapy market include Bayer AG, Endo Pharmaceuticals, Inc., Novartis AG, and Allergen plc.

The CAGR for theglobal testosterone replacement therapy marketis estimated to be -4.20% over the period between 2016 and 2024. The negative growth rate of the global market is expected to take the market value from US2.0 bn in 2015 to a decreased value of US$1.3 bn by 2024-end.

High Incidence of Hypogonadism to Drive Market Demand

Research studies suggest that around 30% of all men suffer from testosterone deficiency, which has driven demand within the global market for testosterone replacement therapy. Furthermore, the population demographic of men in the age range of 40-79 years is more likely to suffer from testosterone deficiency. The need for mutation or having an offspring amongst men in the aforementioned age range has driven demand within the global market.

Enquiry for Discount onTestosterone Replacement Therapy Market Report

Moreover, the geriatric population has been on a rise, which underhandedly contributes to market growth. Several campaigns aimed at educating people about the benefits of testosterone replacement therapy have been an important propeller of demand within the global market. It is anticipated that more people suffering from testosterone deficiency would resort to these therapies over the coming years.

Side Effects of Testosterone Replacement Therapy Could Obstruct Market Growth

Despite the rising awareness amongst the masses about the advantages of testosterone replacement therapies, the market growth is hindered by the apprehension of the people. The chances of developing metabolic disorders are higher in men who undergo testosterone replacement therapies. Furthermore, the risk of developing cardiovascular diseases also discourages people from resorting to testosterone replacement therapies. The FDA has also cautioned people about the use of such therapies by issuing strict warnings, which has further obstructed the growth of the global market.

Contact Us

Transparency Market ResearchAlbany, NY 12207United StatesTel: +1-518-618-1030Website:www.transparencymarketresearch.comEmail:[emailprotected]Research Blog:https://theglobalhealthnews.com/

Go here to see the original:
Testosterone Replacement Therapy Market To Witness Huge Growth in 2024 - Downey Magazine

Archives